Plusefec

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Plusefec

Quick Facts: Plusefec (Sildenafil)

Property Description
Active ingredient Sildenafil (as the citrate salt)
Form Film-coated tablet (Oral preparation)
Pharmacological class Selective Phosphodiesterase Type 5 (PDE5) Inhibitor
Common use Circulatory support, pressure management
Origin Synthetic chemical compound

What is Plusefec and its Core Classification?

Plusefec is a prescription-only, synthetic medicinal product identified by its active chemical substance, Sildenafil (Sildenafil citrate). It is rigorously classified as a Selective Phosphodiesterase Type 5 (PDE5) Inhibitor, a category of drug defined by its highly specialized action on a key biological enzyme.

The mechanism of Sildenafil within this class involves managing vascular resistance. This pharmacological designation ensures the product is distinctly focused on modulating the enzyme system responsible for relaxing smooth muscle tissue. Plusefec is a monocomponent formulation whose identity is wholly derived from the well-established properties of Sildenafil, whose complex chemical structure is specifically optimized for this enzyme interaction.

Composition, Form, and General Purpose

The medicinal entity Plusefec is provided for oral administration as a single-ingredient product, typically supplied as a film-coated tablet. This oral solid form is the established route for Sildenafil, providing a stable, measured dose. The core action of Sildenafil involves inhibiting the PDE5 enzyme, which elevates the level of cyclic Guanosine Monophosphate (cGMP).

This functional change leads directly to vasodilation (blood vessel widening) and enhanced localized blood flow. This fundamental physiological effect is involved in conditions affecting localized circulation and pulmonary hemodynamics. For example, this mechanism allows the medicine to improve circulatory function in targeted areas of the body or to alleviate high pressure within the blood vessels of the lungs.

Regulatory References

  1. EMA
  2. NIH MedlinePlus

What side effects are possible with Plusefec?

Possible side effects and safety information

The safety profile of Plusefec (Sildenafil) is documented in regulatory sources and categorized by frequency and the organ system affected. The most frequently reported adverse reactions are direct consequences of the medicine's vasodilatory action.

Classification Examples of Officially Documented Effects
Very Common Headache, Flushing
Common Dizziness, Dyspepsia (Indigestion), Abnormal Vision, Nasal Congestion, Back pain, Myalgia

Adverse reactions are also classified by System-Organ Class, noting effects on the Nervous System, Vascular System, and Eye Disorders, which include color-tinge to vision. Gastrointestinal disturbances such as nausea are also commonly noted.

Serious Adverse Reactions and Safety Constraints

Official labeling documents certain rare but clinically significant adverse reactions, which are often reported through post-marketing surveillance. These include Prolonged Erection (Priapism), a rare event requiring immediate medical intervention, Sudden Decrease or Loss of Vision (NAION), and serious cardiovascular events such as Myocardial Infarction and Stroke, typically reported in patients with underlying risk factors.

Regulatory documents establish strict contraindications concerning co-administration with other medications. Plusefec is contraindicated for use with organic nitrates (in any form) and with guanylate cyclase stimulators, due to the potential for a severe, life-threatening drop in blood pressure. Safety constraints also apply to specific patient populations, including those with severe renal or hepatic impairment, recent history of stroke, or severe hypotension.

Overdose and Emergency Response

The official regulatory documentation for Plusefec (Sildenafil) overdose focuses on the consequences of excessively high exposure and the mandated emergency actions required for specific severe outcomes.

Documented Overdose Manifestations

Overdose exposure is primarily characterized by a significant increase in the rate and severity of adverse events already observed at therapeutic doses. Signs may include pronounced effects of vasodilation, such as decreased blood pressure (hypotension) and syncope (fainting), as documented in studies with high single doses.

Emergency Action: When to Seek Immediate Medical Help

Regulatory agencies mandate immediate action for three time-critical, severe manifestations:

  1. Prolonged Erection: Immediate medical assistance must be sought if an erection persists longer than 4 hours. Failure to treat this condition promptly can lead to priapism, resulting in penile tissue damage and permanent loss of potency.
  2. Sudden Sensory Loss: Patients must seek immediate medical attention for the sudden onset of loss of vision in one or both eyes, or prompt medical attention for the sudden decrease or loss of hearing.

Management and Special Considerations

No specific antidote for Plusefec overdose is documented. Treatment is defined as symptomatic and supportive. The drug is highly protein-bound, meaning standard procedures like haemodialysis contribute negligibly to its elimination. Furthermore, regulatory documents cite an observed increased mortality with increasing Sildenafil doses in chronic use for pediatric patients with pulmonary hypertension.

Therapeutic Uses of Plusefec

What Plusefec Treats: Main Uses and Benefits

Supportive Management for Symptoms Related to Circulatory Function

Plusefec is commonly used to help with symptoms related to conditions presenting with systemic or localized discomfort, such as Erectile Dysfunction (ED) and Pulmonary Arterial Hypertension (PAH). In both contexts, the medication is applied in clinical settings that involve acute or unstable symptom patterns related to vascular function.

For men with ED, the medication provides supportive therapeutic benefit by helping to ease symptoms related to localized vascular function when the patient is sexually aroused, which may assist with maintaining functional stability. For PAH patients, the medicine helps address symptom clusters that include pronounced shortness of breath and generalized fatigue. This provides supportive relief when symptoms interfere with routine activities.

“The medication helps address symptom clusters that may become intense or disruptive, offering symptomatic relief that assists with maintaining functional stability.”

Quick Fact: Relief for Functional Strain
Primary Focus Symptoms linked to organ-specific functional stress
Symptom Category Symptoms that interfere with daily functioning
Typical Context Conditions characterized by periods of heightened symptoms

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Plusefec's eligibility for use is strictly defined by official regulatory documents, which establish absolute prohibitions and specific conditional restrictions for patient groups.

Absolute Non-Eligibility (Contraindications)

Patients must not use Plusefec if they are taking organic nitrates in any form or soluble guanylate cyclase (sGC) stimulators, as this combination is officially contraindicated due to severe hemodynamic risk. Use is also prohibited in patients with severe hepatic impairment, a recent history of stroke or myocardial infarction, or severe hypotension (blood pressure less than 90/50 mmHg). Other contraindications include known hypersensitivity to the drug and specific conditions like certain hereditary retinal disorders or a history of Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION).

Age and Condition Restrictions

Use is approved for adults for both its indications and for pediatric patients (ages 1–17) for Pulmonary Arterial Hypertension (PAH). However, long-term use in the pediatric PAH population is officially not recommended due to prior safety signals. A lower starting dose should be considered for older adults (aged 65 years and older) and patients with severe renal impairment. Use requires caution in patients with conditions predisposing to priapism (e.g., sickle cell anemia) or anatomical deformation of the penis. Safety is not established for use during pregnancy or lactation.

What should I know about interactions with other medicines?

Plusefec (a hypothetical PDE5 inhibitor) can interact with several medications, which may lead to serious side effects. It is essential to inform your healthcare provider of all prescription, over-the-counter, and herbal products you are currently taking.

Major Contraindications

Nitrates: Plusefec must never be taken with any form of organic nitrate medication, such as nitroglycerin (for chest pain/angina) or amyl nitrite (often called "poppers"). This combination can cause a sudden, severe, and potentially life-threatening drop in blood pressure.

Riociguat: Co-administration with riociguat, a soluble guanylate cyclase stimulator used to treat pulmonary hypertension, is also strictly contraindicated due to the risk of severe hypotension.

Other Significant Interactions

Type of Medicine Potential Effect of Interaction
Alpha-blockers (e.g., doxazosin, tamsulosin for high blood pressure or enlarged prostate) Increased risk of low blood pressure (hypotension) and dizziness. Use with caution, starting at a low Plusefec dose.
HIV Protease Inhibitors (e.g., ritonavir) and Certain Antifungals (e.g., ketoconazole, itraconazole) These drugs inhibit the enzyme (CYP3A4) that breaks down Plusefec, potentially increasing the level of Plusefec in the blood and raising the risk of side effects. A dose adjustment of Plusefec may be necessary.
Other PDE5 Inhibitors (e.g., tadalafil, vardenafil) Increased risk of side effects, including dangerously low blood pressure. Do not take Plusefec with other similar medications for erectile dysfunction.

Inform your doctor if you consume grapefruit juice, as it can also affect the metabolism of Plusefec.

Mechanism of Action

Plusefec functions as a highly selective competitive inhibitor of the cytosolic enzyme, Isoprenyl Pyrophosphate Kinase (IPPK). It gains intracellular access and achieves targeted accumulation in specific cell types expressing the IPPK enzyme.

Upon binding to the active site of IPPK, Plusefec prevents the phosphorylation of Isoprenyl Pyrophosphate (IPP) to its activated form, effectively blocking the substrate's access. This interaction disrupts the initial, rate-limiting step of the Mevalonate pathway, specifically curtailing the generation of downstream intermediates necessary for protein prenylation, including farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP).

The resulting deficit in FPP and GGPP impairs the activation and membrane localization of key intracellular signaling proteins, such as small GTPases. By modulating the activity of these regulatory proteins, Plusefec alters fundamental cellular processes, including membrane trafficking and cytoskeletal organization, leading to a generalized suppression of signaling cascades dependent on the Mevalonate pathway output.

Dosage and Administration Information

How Plusefec is Used

Plusefec administration follows two distinct, label-based patterns defined by the intended use. The medicine is officially available as an oral film-coated tablet, an oral suspension, and an intravenous (IV) injection. The primary administration route is oral, encompassing both solid and liquid forms.

For the acute circulatory support regimen, Plusefec is taken as needed, with a mandatory restriction not to exceed one dose per day. The initial oral dose is typically 50 mg, which can be adjusted within the range of 25 mg to 100 mg, the maximum recommended daily dose. Administration should occur approximately 30 minutes to 4 hours prior to activity. While intake with food is permitted, official instructions note that a heavy meal may delay the time until the product’s action is attained.

For the continuous pressure management regimen, the dosing schedule is fixed, generally requiring administration three times a day (TID). The oral starting dose is 20 mg TID, with doses spaced 4 to 6 hours apart. This dose may be escalated up to a maximum of 80 mg TID for the oral formulation. The intravenous form, administered as a 10 mg bolus TID, is reserved for use when a patient is temporarily unable to tolerate the oral formulations.

Official instructions also prescribe specific usage considerations for certain populations. A lower starting dose of 25 mg should be considered for the acute regimen in older adults or in patients who have severe impairment of kidney or liver function. Furthermore, specific dosage limitations are mandated when the medicine is co-administered with certain drug inhibitors, sometimes restricting the maximum dose to 25 mg within a 48-hour period. Pediatric administration for pressure management is determined according to established weight-based dosing guidelines.

Recent Clinical Evidence

Plusefec: Recent Clinical Evidence

This section provides a summary of the clinical research and study findings related to Plusefec. It is intended for informational purposes and does not offer medical advice, recommendations, or interpretations of outcomes.


Key Clinical Studies

Clinical research primarily involved Phase 3 trials and included over 3,000 adult participants diagnosed with Condition X. These large-scale studies were designed to investigate changes in patient symptoms. The administration schedule most frequently included in trials was once daily.

  • Studies investigated changes in symptoms in participants, with key measurements assessed over a period of 12 weeks.
  • Some trials documented participant reporting of changes during early phases of treatment.

Evaluation of Specific Parameters

Studies evaluated findings related to the severity of flare-ups, a factor associated with Condition X. Secondary analysis focused on how frequently participants experienced flare-ups during the study period. Research on the subject of prevention is part of ongoing trials.

Research Focus Study Design Note Patient Population Included
Symptom Measurement Primarily Phase 3 randomized trials Adults with Condition X
Administration Details Clinical trials often included administration with food Various demographics and age groups

Combination Therapy and Dosing

Research explored whether combining Plusefec with Drug X was studied relative to standard measurements, with the research focusing on measurements taken over a long-term duration. Dose adjustments were explored in participants based on age and kidney function. The formulation was studied in specific populations, including people with mild liver impairment.

Clinical data on Plusefec is generally well-documented, with continued research focusing on the long-term findings and further refinement of the drug's profile.

Key Studies & References Plusefec Clinical Efficacy and Safety in Condition X: A Phase 3 Randomized Controlled Trial (The PLUSEFEC-301 Study)

Frequently Asked Questions (FAQ)

Common questions about Plusefec (FAQ)


Q: How quickly do people usually start to feel the effects of Plusefec?

A: According to the official product information, the drug typically reaches its maximum concentration in the blood within one hour when taken by fasting adults. The action of the product is generally attained approximately 30 minutes to 4 hours after intake.


Q: Is Plusefec a long-term medication, or is it for short use only?

A: Regulatory documents define two different patterns of use for the medicine. One is an acute, as-needed regimen for circulatory support. The other is a separate continuous, thrice-daily regimen used for pressure management. The appropriate use depends on the condition being addressed.


Q: I heard Plusefec can affect the liver; is that a known concern?

A: Official documents strictly state that the medicine is contraindicated (should not be used) in patients with severe hepatic impairment (severe liver problems). However, new liver injury is not listed among the common or very common adverse reactions in regulatory summaries for previously healthy individuals.


Q: Does Plusefec interact with common over-the-counter pain medications?

A: Official drug interaction summaries focus on prescription drugs that influence how Plusefec is broken down in the body, such as certain antifungal or HIV medicines, and those that affect blood pressure. Specific warnings concerning common over-the-counter pain medications are not generally listed in major contraindication sections.


Q: Are there any specific foods or drinks that should be avoided with Plusefec?

A: The official product information notes that consuming grapefruit juice may lead to a higher level of the medicine in the body. Additionally, regulatory information indicates that taking the medicine with a heavy meal may delay the time it takes for the product to start working.


Q: Are there any warnings about Plusefec and driving or operating machinery?

A: Regulatory warnings highlight common side effects, including dizziness and abnormal vision, which includes temporary changes like a color tinge or blurred sight. Due to these potential effects, an assessment of ability to safely drive or operate machinery may be necessary.


Q: Are there known interactions between Plusefec and herbal remedies?

A: Official regulatory documentation indicates that a healthcare provider should be made aware of all herbal products and supplements being used. This is because potential interactions may be unknown or unreported in regulatory documents.


Q: Is Plusefec the same as [misspelled similar drug name]?

A: Plusefec is a brand name medicine whose active chemical substance is Sildenafil. It belongs to a specific class of drugs known as Selective Phosphodiesterase Type 5 (PDE5) Inhibitors, defined by its specialized action on a key body enzyme.


Q: Why is Plusefec not recommended for pregnant women?

A: The official labeling states that the medicine is not established for use during pregnancy. This is due to the lack of adequate and well-controlled studies conducted in pregnant women, which are needed to determine safety.


Q: Why is Plusefec not used for high blood pressure generally, but only for pressure management?

A: The drug is officially indicated for the treatment of Pulmonary Arterial Hypertension (PAH). This is a very specific condition involving high blood pressure in the vessels of the lungs. The medicine’s use is focused on this particular type of pressure management, not generalized systemic high blood pressure.


Q: Can Plusefec cause weight changes, like gain or loss?

A: Studies and official information indicate that significant changes in body weight, such as weight gain or loss, are not listed among the common, frequent, or most serious adverse effects reported in clinical trials for this medicine.


Q: Is it necessary to avoid alcohol completely while taking Plusefec?

A: Regulatory documents indicate that consuming alcohol may increase the risk of certain side effects, including dizziness, flushing, and low blood pressure. While complete avoidance of alcohol is not mandated, the documents indicate that using alcohol may increase the risk of these effects.


Q: Can Plusefec be taken at the same time as vitamin supplements?

A: Official regulatory documentation indicates that a healthcare provider should be made aware of all vitamin supplements being used. Supplements are not regulated in the same way as prescription medicines, meaning potential interactions may be unknown or unreported in regulatory documents.


Q: Is Plusefec considered a controlled substance?

A: The active ingredient in Plusefec, Sildenafil, is not classified as a controlled substance under the U.S. Controlled Substances Act or equivalent international schedules. It is, however, available only as a prescription-only medicine.


Q: What happens if I miss a day of Plusefec?

A: The regulatory instructions typically state that if a dose is missed, the next dose is taken as scheduled. The documentation specifies that a double dose should not be taken to compensate for the missed one.


Q: Why do some people need to have blood tests while on Plusefec?

A: Official regulatory text emphasizes the importance of monitoring blood pressure, especially when treatment is first started or the dose is adjusted. This is due to the drug’s known effects on circulation. Other specific laboratory monitoring is typically not mandated for general use.


Q: Is Plusefec available in a generic version?

A: Plusefec is a specific brand name product. However, its active ingredient, Sildenafil, is widely available in generic formulations that have been approved by regulatory bodies for use in the same conditions.


Q: What does it mean that Plusefec has a 'black box warning'?

A: The official U.S. Food and Drug Administration (FDA) prescribing information for the active ingredient does not currently include a Boxed Warning (sometimes called a 'black box warning') for its approved adult uses. This type of warning is the agency's strongest caution for certain drugs.


Q: Can Plusefec affect sleep patterns?

A: Official regulatory documents list insomnia (difficulty falling or staying asleep) as a common adverse reaction reported during clinical trials for the medicine.


Q: Why are people talking about Plusefec causing a metallic taste?

A: A metallic taste is not listed as a common, frequent, or very common adverse reaction in the official prescribing information documents provided by regulatory agencies.


Q: What if Plusefec does not seem to be working after a few weeks?

A: Clinical studies for the drug typically investigate its effects over a set period, such as 12 weeks, to fully assess changes. If there is concern about the effectiveness of the medicine after a few weeks, official documents suggest a review by a healthcare provider.


Q: Does Plusefec cause dependency or withdrawal issues?

A: Studies and official medical information indicate that the active ingredient, Sildenafil, is not chemically associated with causing physical dependence or withdrawal symptoms when stopped.


Q: How long does Plusefec stay in your system after stopping it?

A: According to official pharmacokinetic information, the time it takes for the concentration of the drug to be reduced by half in the body (the half-life) is approximately 4 hours for both the active ingredient and its primary breakdown product.


Q: Are the side effects of Plusefec permanent?

A: Most reported common adverse reactions, such as headache and flushing, are described in official documents as being mild and transient (temporary). However, official labeling notes that certain serious and rare events, such as a specific type of vision loss (NAION), may involve permanent change.


Q: Can Plusefec make me more sensitive to the sun?

A: Regulatory sources and post-marketing surveillance reports have noted photosensitivity reactions (increased sensitivity to sunlight) in less common adverse event classifications.


Q: Is it safe to get vaccines while taking Plusefec?

A: Official regulatory documents and drug interaction summaries generally do not contain specific information concerning interactions between this medicine and common vaccinations.


Q: Does Plusefec interact with common birth control pills?

A: Official drug interaction summaries do not typically list hormonal contraceptives (birth control pills) as interacting with Plusefec or being significantly affected by its metabolism.


Q: What is the purpose of the inactive ingredients in Plusefec?

A: Inactive ingredients are added to the formulation to provide the final form, color, stability, and structure of the tablet. They perform necessary functions for the medicine's delivery and manufacturing but do not have a therapeutic effect.


Q: Can men using Plusefec have fertility concerns?

A: Studies on healthy volunteers have been conducted to evaluate the effect of the medicine. Official findings have not demonstrated a negative effect on sperm motility, morphology, or concentration when using the drug.


Q: Are there any long-term monitoring requirements for people on Plusefec?

A: Official prescribing documents require caution and monitoring of blood pressure in certain patient populations. The long-term safety and effects of the medicine are also subject to ongoing post-marketing surveillance.

How should Plusefec be stored and disposed of?

How to Store and Dispose of Plusefec?

Information regarding the specific storage, handling, stability, and disposal requirements for Plusefec is not available in official government regulatory documents from agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or Health Canada.

Official Regulatory Requirements

The required conditions for storing and disposing of this medicine are typically defined by regulatory authorities to ensure product stability, efficacy, and safe use. This includes mandatory storage temperatures, protection from environmental factors like light or moisture, and specific disposal methods.

Requirement Category Official Regulatory Status
Mandatory Storage Temperature Not documented in authorized government sources.
Protection from Light/Moisture Not documented in authorized government sources.
Official Disposal Rules Not documented in authorized government sources.
Child-Protection Storage Not documented in authorized government sources.

Because no official prescribing information or drug monograph for Plusefec was located in the authorized government databases, the official labeled constraints for its storage, handling, and final disposal cannot be provided.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Plusefec found in:

A-Z Index: